(A) DoHH2 cells were incubated with either diluent or sorafenib at 1.25, 2.5 and 3.75 μM concentration for 48h. Then, cells (1 × 105/100 μl) were stained for CD20, CD46, CD55 and CD59 and analyzed in a FACSCalibur using Cell-Quest Pro software version 5.2. (B) DoHH2, Daudi, Raji or Ramos cells were incubated with either diluent or sorafenib at appropriate concentrations for 48h. Then, equal numbers of cells (1 × 105/well) were incubated for 1h with serial dilutions (from 1 to 100 μg/ml) of rituximab in the presence of 10% human AB serum as a complement source. Cell viability was measured with a MTT assay. The survival of cells is presented as percentage of corresponding diluent- or sorafenib-pretreated cells without rituximab. *P<0.05 (Student's t -test).
